ClinicalTrials.gg
Status unknownNCT05470855Updated Jan 12, 2023

Protective Effect, Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Anhui Province

A Phase 4 interventional study of Live attenuated varicella vaccine in Varicella, sponsored by Sinovac (Dalian) Vaccine Technology Co., Ltd.. Status unknown at 5 sites in China. Open to participants aged 1 Year to 12 Years. Per ClinicalTrials.gov, last updated 2023-01-12.

Sponsored by Sinovac (Dalian) Vaccine Technology Co., Ltd. (part of Sinovac Biotech Co., Ltd) · Phase 4, Interventional, and Prevention

The sponsor has not verified this record recently (last verified Jul 2022), so the status shown — last known as Active, not recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
45,400
Allocation
Non-randomized
Ages
1 Year to 12 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies testing Chickenpox Vaccine in Chickenpox — 5 open to participants now, 7 under way, 4 of them phase 3. Chickenpox Vaccine · Chickenpox.

Planned enrollment
2nd of 36
45,400 · median 404
Started
2022
with 2 others
Phase 4
14 of 36
2 open now
Registered
28th of 36
by date
Lead sponsor
11 of 36
Sinovac (Dalian) Vaccine Technology Co., Ltd.

Among the 36 studies testing Chickenpox Vaccine in Chickenpox, this one is the 2nd largest by planned enrollment, is one of 3 that started in 2022, is one of 14 in phase 4, and was the 28th registered.

Chickenpox

180 studies on the registry are indexed under Chickenpox; 28 are open to participants now.

Browse Chickenpox studies →

Open to participants now

5 of the 36 studies testing Chickenpox Vaccine in Chickenpox are open now, in 7 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About Chickenpox Vaccine

Chickenpox Vaccine: first FDA approval 1995 (Varivax). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 16 Chickenpox studies recruiting now, 3 (19%) set no upper age limit and 13 (81%) stop at 75 or younger; 12 take children under 18; 13 take healthy volunteers.

This study: 1 Year to 12 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing Chickenpox Vaccine in Chickenpox, or all of them as a file.
02

Study summary

This is Phase 4 clinical trial of live attenuated varicella vaccines manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd .The purpose of this study is to evaluate the protective effect of varicella vaccine in children aged 1-12 years and the correlation between varicella antibody and protective effect,to evaluate the immunogenicity and safety of varicella vaccine in children aged 1-12 years.

Read the detailed description

This study is Phase Ⅳ clinical trial.The experimental vaccine manufactured by Sinovac(Dalian) Vaccine Technology Co., Ltd.This clinical trial consists of four parts,and A total of 45400 subjects will be enrolled.

Study 1,45000 subjects including 15000 subjects aged 1-3 years with no history of varicella vaccination ,15000 subjects aged 4-6 years with a history of 1 dose of varicella vaccine,15000 subjects aged 7-12 years with a history of 1 dose of varicella vaccine will be enrolled to evaluate protective effect of varicella vaccine. There will be 7500 subjects in the experimental group and 7500 in the control group in each age group.And subjects who voluntarily receive varicella vaccine will be included in the experimental group and other subjects will be included in the control group.All subjects in the experimental group will receive one dose of varicella vaccine.

Study 2,400 healthy children including 100 subjects aged 1-3 years with no history of varicella ,150 subjects aged 4-6 years(50 children with no history of varicella vaccination and 100 children with a history of one dose of varicella vaccine),150 subjects aged 7-12 years (50 children with no history of varicella vaccination and 100 children with a history of one dose of varicella vaccine),each subject will receive one or two doses (0,3 months) of varicella vaccine.

Study 3,30000 subjects from study 1 will be enrolled to conduct safety observation study,all adverse events of all subjects will be collected.

Study 4,Herpes fluid collected from study 1 varicella cases will be used to conduct etiological study on the pathogenic strains of varicella cases.

03

Conditions studied

  • Varicella

Browse trials for

04

Who can participate

Ages eligible
1 Year to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Study 1: Inclusion criteria for a protective effect study of varicella vaccine:

  • Healthy children aged 1-12 years without a history of varicella;
  • The subjects and/or guardians can understand and voluntarily sign the form (For subjects aged 8 years and above, both subjects and guardians need to sign the informed consent form);

Study 2: Inclusion criteria for immunogenicity and safety evaluation of varicella vaccine:

  • Healthy children aged 1-12 years without a history of varicella;
  • The subjects and/or guardians can understand and voluntarily sign the informed consent form (For subjects aged 8 years and above, both subjects and guardians need to sign the informed consent form);
  • The subjects and their guardians voluntarily participate in the study and are able to follow all study procedures;
  • Proven legal identity.

Study 3: Inclusion criteria for safety evaluation of mass vaccination of varicella vaccine :

  • Healthy children aged 1-12 years without a history of varicella;
  • The subjects and/or guardians can understand and voluntarily sign the informed consent form (For subjects aged 8 years and above, both subjects and guardians need to sign the informed consent form);
  • The subjects and their guardians voluntarily participate in the study and are able to follow all study procedures;
  • Proven legal identity;
  • Subjects'guardians can fill in adverse events using mobile apps;

Study 4: Inclusion criteria for etiological study on the pathogenic strains of varicella cases:

  • Varicella cases among study 1 enrolled subjects who signed informed consent for biological samples collection.

Exclusion Criteria:

  • Received two doses of varicella vaccine from other manufacturers(applied to study 1 exclusion criteria);
  • Received two doses of varicella vaccine;
  • History of severe allergic reactions to vaccines (e.g.acute anaphylaxis, angioneurotic edema, dyspnea, etc.);
  • Any confirmed or suspected immunodeficiency disease, including (HIV) infection;
  • Axillary temperature >37.0°C;
  • Receipt of other drugs in the past 30 days;
  • Receipt of attenuated in the past 28 days;
  • Receipt of inactivated or subunit vaccines in the past 7 days;
  • According to the investigator's judgment, the subject has any other factors that are not suitable for participating in the clinical trial.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
45,400 participants (estimated)

Study arms

  • Experimental
    Experimental Group in Protective effect study

    22500 subjects including 7500 subjects aged 1-3 years with no history of varicella vaccination,7500 subjects aged 4-6 years with a history of 1 dose of varicella vaccine,7500 subjects aged 7-12 years with a history of 1 dose of varicella vaccine will receive one dose of varicella vaccine.

    Biological: Live attenuated varicella vaccine

  • No intervention
    Control Group in Protective effect study

    22500 subjects including 7500 subjects aged 1-3 years with no history of varicella vaccination,7500 subjects aged 4-6 years with a history of 1 dose of varicella vaccine,7500 subjects aged 7-12 years with a history of 1 dose of varicella vaccine.

  • Experimental
    Safety group

    30000 subjects from study 1 will be enrolled to conduct safety observation study,all adverse events of all subjects will be collected.

    Biological: Live attenuated varicella vaccine

  • Experimental
    Etiological study group

    Herpes fluid collected from varicella cases in study 1 will be used to conduct etiological study on the pathogenic strains of varicella cases.

    Biological: Live attenuated varicella vaccine

Interventions

  • The live attenuated varicella vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd. Live attenuated varicella-virus in 0.5 mL injection water with sucrose,sodium glutamate,sodium chloride,potassium chloride, sodium dihydrogen phosphate, potassium dihydrogen phosphate per injection.The routine of administration is intramuscular injection into deltoid region of the lateral upper arm.

06

What researchers measure

Primary outcomes

  1. The incidence density

    The incidence density will be calculated by the number of confirmed cases of varicella at 42 days after vaccination.

    Time frame: 42 days after vaccination

  2. The protection rate

    The protection rate will be calculated by the number of confirmed cases of varicella at 42 days after vaccination.

    Time frame: 42 days after vaccination

Secondary outcomes

  1. GMT of varicella antibody

    GMT of varicella antibody at 42 days after varicella vaccination.

    Time frame: 42 days after varicella vaccination

  2. GMI of varicella antibody

    GMI of varicella antibody at 42 days after varicella vaccination.

    Time frame: 42 days after varicella vaccination

  3. Positive rates of varicella antibody

    Positive rate of varicella antibody at 42 days after varicella vaccination.

    Time frame: 42 days after varicella vaccination

  4. Immunogenicity index-GMT of varicella antibody

    GMT of varicella antibody at 4 months after varicella vaccination.

    Time frame: 4 months after varicella vaccination

  5. Immunogenicity index-GMI of varicella antibody

    GMI of varicella antibody at 4 months after varicella vaccination.

    Time frame: 4 months after varicella vaccination

  6. Immunogenicity index- positive rates

    Positive rates of varicella antibody at 4 months after varicella vaccination.

    Time frame: 4 months after varicella vaccination

  7. The incidence of adverse events, serious adverse events and adverse reactions

    The incidence of adverse events, serious adverse events and adverse reactions at 14 days after varicella vaccination.

    Time frame: 14 days after varicella vaccination

  8. Incidence of adverse events, serious adverse events and adverse reactions

    The incidence of adverse events, serious adverse events and adverse reactions at 42 days after varicella vaccination.

    Time frame: 42 days after varicella vaccination.

  9. Safety index-Incidence of adverse events, serious adverse events and adverse reactions

    The incidence of adverse events, serious adverse events and adverse reactions in 3 months after varicella vaccination.

    Time frame: 3 months after varicella vaccination

  10. Safety index-incidence of adverse events, serious adverse events and adverse reactions

    The incidence of adverse events, serious adverse events and adverse reactions in 6 months after varicella vaccination.

    Time frame: 6 months after varicella vaccination

  11. Safety index- incidence of adverse events, serious adverse events and adverse reactions

    The incidence of adverse events, serious adverse events and adverse reactions in 9 months after varicella vaccination.

    Time frame: 9 months after varicella vaccination

  12. The incidence of adverse events, serious adverse events and adverse reactions

    The incidence of adverse events, serious adverse events and adverse reactions in 12 months after varicella vaccination.

    Time frame: 12 months after varicella vaccination

07

Study locations

5 sites
  • Susong County Center for Disease Control and Prevention
    Anqing, Anhui 246525, China
  • Laian Center for Disease Control and Prevention
    Chuzhou, Anhui 239299, China
  • Funan County Center for Disease Control and Prevention
    Fuyang, Anhui 236399, China
  • Huoqiu County Center for Disease Control and Prevention
    Liu'an, Anhui 237483, China
  • Ningguo Center for Disease Control and Prevention
    Xuancheng, Anhui 242399, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2022 to primary completion in Nov 2022, 4 months.

Of 14 phase 4 interventional studies under Chickenpox, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 22. This study's 4 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 12, 2022
First posted
Jul 22, 2022
StartActual
Jul 6, 2022
Primary completionActual
Nov 30, 2022
CompletionEst.
Feb 10, 2023
Last update
Jan 12, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 12, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05470855
Responsible party
Sponsor
First posted
Jul 22, 2022
Start date
Jul 6, 2022
Primary completion
Nov 30, 2022
Completion
Feb 10, 2023 (estimated)
Last update
Jan 12, 2023

Study contacts

Jihai Tang, Master
principal investigator · Anhui Provincial Center for Disease Prevention and Control

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Chickenpox Vaccine

Start the discussion